A Trial of the Senolytic Fisetin as a Treatment for Older SARS-CoV-2 Patients
We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients.
Link: https://doi.org/10.1111/jgs.17416
Source: Fight Aging! - Category: Research Authors: Reason Tags: Daily News Source Type: blogs
More News: Cardiology | Cardiovascular | Clinical Trials | COVID-19 | Diabetes | Eating Disorders & Weight Management | Endocrinology | Heart | National Institutes of Health (NIH) | Nurses | Nursing | Obesity | Orthopaedics | Osteoporosis | Research | Respiratory Medicine | SARS | Study | Urology & Nephrology